Recoverable Foundation

Recovery Library

Doc #124 — Veterinary Medicine Under Nuclear Winter

Maintaining NZ Livestock Health When Animal Health Is Food Security

Phase: 2 (Years 1–3, with ongoing relevance through Phase 4) | Feasibility: [B] Materials and knowledge base exist, but capability must be built under degraded pharmaceutical supply and increased disease pressure

Unreliable — not for operational use. Produced by AI under human direction and editorial review. This document contains errors of fact, judgment, and emphasis and has not been peer-reviewed. See About the Recovery Library for methodology and limitations. © 2026 Recoverable Foundation. Licensed under CC BY-ND 4.0. This disclaimer must be included in any reproduction or redistribution.

EXECUTIVE SUMMARY

New Zealand’s food security depends on its livestock. Approximately 6.3 million dairy cattle, 3.9 million beef cattle, 25.5 million sheep, and 830,000 deer convert grass into the calories, protein, and fat that feed the nation (Doc #82).1 When those animals get sick — and under nuclear winter conditions, they will get sick more often — the consequences are not measured in individual animal welfare alone but in national food supply. A mastitis outbreak that reduces dairy output by 15% is a food crisis. An internal parasite burden that drops lamb growth rates by 30% is a protein deficit. A facial eczema season that kills 5% of the dairy herd and permanently damages the livers of another 20% is an irreversible loss of productive capital.

NZ enters this scenario with a veterinary profession of approximately 3,000–3,200 registered veterinarians, of whom roughly 40–50% work in production animal practice.2 The veterinary pharmaceutical supply — antibiotics, antiparasitics, anti-inflammatories, vaccines, and mineral supplements — is almost entirely imported, and will deplete along the same trajectory as human pharmaceuticals (Doc #116). The veterinary workforce, while skilled and experienced, is concentrated in regions and practice types that may not align with post-event priorities.

The core problem this document addresses is: how does NZ maintain livestock health when the pharmaceutical tools that underpin modern animal husbandry are finite and declining, the disease environment is worsening, and every animal death or production loss translates directly into less food for people?

The strategy has four elements:

  1. Triage the veterinary pharmaceutical supply. Integrate veterinary stocks into the national pharmaceutical inventory (Doc #116, Section 6). Prioritise drugs that protect food production — anthelmintics, mastitis treatments, metabolic supplements — over companion animal medications. Identify dual-use drugs suitable for human medicine.
  2. Shift from treatment to prevention. Intensive veterinary medicine — treating sick animals with pharmaceuticals — must give way to preventive husbandry: genetic selection for disease resistance, pasture management to break parasite cycles, nutritional management to prevent metabolic disorders, and biosecurity to prevent disease spread between herds.
  3. Develop locally producible veterinary treatments. Herbal drenches, mineral supplements from NZ geological sources, wound care from locally produced materials, and biological pest control are not replacements for modern veterinary pharmaceuticals, but they extend the toolkit beyond zero when pharmaceutical stocks deplete.
  4. Redeploy the veterinary workforce. Companion animal veterinarians, equine specialists, and those in non-clinical roles must be redeployed to production animal practice and trained in pre-pharmaceutical husbandry techniques.

Key honest uncertainty: The interaction between nuclear winter stress (cold, reduced feed, UV damage) and livestock disease pressure is not well-studied. The estimates in this document of disease incidence increases under these conditions are based on extrapolation from known stress-disease relationships, not from empirical data on livestock under nuclear winter. They could be significantly wrong.

Contents

Phase 1 — First two weeks [URGENT]

  1. Integrate veterinary pharmaceutical stocks into the national inventory (Doc #116). Provet NZ (EBOS Group subsidiary) is the primary distributor; PGG Wrightson and Farmlands hold significant retail stocks. Inventory all veterinary antibiotics, anthelmintics, anti-inflammatories, anaesthetics, vaccines, and mineral supplements. [Phase: 1 — URGENT]
  2. Identify dual-use veterinary pharmaceuticals for potential human allocation. Convene a joint veterinary-medical review board. Priority candidates: penicillin, amoxicillin, trimethoprim-sulfa, ketamine, lidocaine, ivermectin, meloxicam. Maintain sufficient veterinary supply for essential livestock treatment. [Phase: 1 — URGENT]
  3. Issue guidance to all veterinary practices: conserve pharmaceutical stocks. No routine prophylactic antibiotic use. Treatment only for confirmed clinical disease with production-relevant animals. [Phase: 1 — URGENT]

Phase 1 — First three months [HIGH PRIORITY]

  1. Establish regional veterinary triage centres. Concentrate veterinary expertise at district level (one per region, co-located with major livestock areas — Waikato, Taranaki, Canterbury, Southland, Manawatu, Hawke’s Bay, Northland). Satellite services to remote farms. [Phase: 1]
  2. Begin veterinary workforce redeployment. Register all veterinarians and veterinary nurses nationally. Reassign companion animal practitioners and those in non-clinical roles (regulatory, academic, corporate) to production animal practice. Provide crash-course training in production animal medicine for those without recent large-animal experience. [Phase: 1]
  3. Secure and inventory all veterinary vaccine stocks. Prioritise clostridial vaccines (5-in-1 / 10-in-1), leptospirosis vaccines for dairy cattle, and campylobacter vaccines for sheep. Calculate depletion timelines. [Phase: 1]
  4. Print and distribute veterinary field guides. Concise, illustrated guides for farmers on: recognising common diseases, basic wound care, parasite management without pharmaceuticals, and when to call a veterinarian versus when to manage independently. [Phase: 1]

Phase 2 — Months 3–12 [STRATEGIC]

  1. Implement preventive husbandry programme nationally. Issue guidance on pasture rotation for parasite management, zinc supplementation for facial eczema prevention, shelter provision for cold stress, and breeding for disease resistance. [Phase: 2]
  2. Begin local production of key veterinary inputs. Mineral supplements (zinc oxide from NZ zinc sources, lime for calcium supplementation), wound dressings (honey-based, tallow-based), and herbal anthelmintic research programme. [Phase: 2]
  3. Establish veterinary training programme for farmers and farm workers. Target: basic veterinary skills (wound management, calving assistance, parasite monitoring, body condition scoring) taught to at least one person per farm. [Phase: 2]
  4. Coordinate breeding decisions with disease resistance goals. Facial eczema tolerance, internal parasite resistance (via FEC — faecal egg count — breeding values), and cold tolerance should become primary breeding criteria alongside production traits. [Phase: 2]

Phase 2–3 — Years 1–5 [DEVELOPMENTAL]

  1. Develop biological parasite control. Nematophagous fungi (Duddingtonia flagrans) for pasture larval reduction. Research programme at Massey University or AgResearch.3 [Phase: 2–3]
  2. Establish veterinary knowledge transfer from retiring practitioners. Heritage skills preservation (Doc #160) must include veterinary knowledge — particularly pre-antibiotic treatment methods, surgical techniques for field conditions, and traditional livestock management. [Phase: 2–3]
  3. Develop local vaccine production capability if feasible. Clostridial vaccines are inactivated toxoid vaccines — lower complexity than live-attenuated or recombinant vaccines, but still requiring anaerobic bacterial culture, toxin harvesting, formalin inactivation, adjuvanting, sterility testing, and potency assurance (Section 3.5). Assessment of NZ’s capacity (with existing laboratory infrastructure at Massey University, AgResearch Wallaceville) required. [Phase: 3, Feasibility: B/C]

ECONOMIC JUSTIFICATION

The value of animal health to food security

NZ’s pastoral livestock system produces approximately 15–30 trillion kcal of gross feed energy annually under nuclear winter conditions, converting to roughly 1.5–4.5 trillion kcal of human-available food (Doc #074).4 NZ’s population of approximately 5.1–5.2 million requires roughly 3.6–4.0 trillion kcal per year (assuming 1,900–2,100 kcal per person per day under rationing).5 The margin between livestock food production and population requirement is narrow, particularly at the lower end of estimates.

Disease-related production losses under normal conditions are already significant:

  • Mastitis costs the NZ dairy industry an estimated NZ$180–280 million per year in lost production, treatment costs, and premature culling.6 Under nuclear winter stress, mastitis incidence will increase (Section 3.2), and treatment options will be constrained.
  • Internal parasites (primarily gastrointestinal nematodes) reduce sheep and cattle growth rates by an estimated 10–30% in untreated animals, with young stock most severely affected.7
  • Facial eczema in bad sporidesmin years affects 30–60% of dairy herds in the upper North Island, with production losses of 10–20% in affected animals and mortality of 1–5% in severe cases.8
  • Metabolic disorders (milk fever, ketosis, grass staggers) affect 5–15% of dairy cows annually, with mortality of 1–3% if untreated.9

Under nuclear winter conditions, these losses compound. Stressed, underfed, cold animals are more susceptible to disease. If disease losses increase from a baseline of perhaps 5–10% of total production value to 15–30% — a plausible range given the compounding stressors — the impact on food security is substantial. A 15% disease-related production loss applied to an already-reduced pastoral output could represent the caloric equivalent of feeding 200,000–400,000 fewer people.

Labour investment

Veterinary workforce redeployment: NZ’s approximately 3,000–3,200 veterinarians represent an existing workforce that requires redeployment, not creation. The labour cost is retraining (estimated 2–4 weeks of intensive training for companion animal vets transitioning to production animal work) and redistribution (moving practitioners from urban centres to rural areas).

Farmer veterinary training: Training one person per farm in basic veterinary skills — roughly 45,000–55,000 farms (Stats NZ agricultural census data includes significant variation depending on how “farm” is defined)10 — requires approximately 100–200 person-years of training effort over 2–3 years, delivered through regional veterinary centres and on-farm instruction. This displaces labour from other activities, but the return is substantial: reduced demand on the finite veterinary workforce and earlier detection and management of disease.

Local treatment production: A small team (5–15 people) developing mineral supplements, wound care materials, and herbal preparations. Negligible labour cost relative to value.

Breakeven

The veterinary programme does not have a construction cost to amortise. It is primarily a redeployment and retraining exercise applied to an existing workforce, with modest investment in local production. The “breakeven” is immediate: every animal death prevented and every production loss avoided from the first day of improved veterinary coverage represents food that would otherwise be lost.

1. NZ’S VETERINARY SYSTEM: BASELINE

1.1 The veterinary workforce

NZ has approximately 3,000–3,200 registered veterinarians as of recent Veterinary Council of New Zealand (VCNZ) data.11 The workforce breaks down approximately as follows:

  • Production animal / mixed practice: ~40–50% (~1,200–1,600). These are the veterinarians who treat cattle, sheep, deer, and other livestock. Concentrated in rural areas: Waikato, Taranaki, Canterbury, Southland, Manawatu.
  • Companion animal practice: ~35–40% (~1,050–1,280). Small animal (dogs, cats) and equine practice. Concentrated in urban and peri-urban areas.
  • Non-clinical roles: ~10–15% (~300–480). Regulatory (MPI, NZFSA), academic (Massey University School of Veterinary Science), corporate (pharmaceutical companies, agribusiness), laboratory, and public health.
  • Veterinary nurses/technicians: Approximately 2,000–2,500 additional trained support staff across practices.12

Key vulnerability: NZ relies heavily on internationally trained veterinarians. A significant proportion of production animal veterinarians are graduates of overseas veterinary schools (particularly the UK, Australia, and South Africa) who came to NZ for work. If any have departed or are unable to practice, the effective workforce shrinks. The VCNZ register should be audited immediately post-event to establish the actual available workforce.

1.2 Veterinary pharmaceutical supply

NZ imports essentially all veterinary pharmaceuticals. The supply chain mirrors the human pharmaceutical chain (Doc #116, Section 1):

  • Manufacturers (global): Zoetis, MSD Animal Health (Intervet), Boehringer Ingelheim, Elanco, Virbac, and others produce the active ingredients and finished products.
  • Distribution: Provet NZ (EBOS Group subsidiary) is the dominant veterinary pharmaceutical distributor.13 PGG Wrightson and Farmlands cooperatives hold significant retail stocks at their branch networks (approximately 90 and 80 stores respectively across NZ).14
  • On-farm stocks: Many farms, particularly dairy operations, hold weeks to months of commonly used veterinary products — intramammary antibiotic tubes, pour-on anthelmintics, injectable antibiotics, mineral drenches, and vaccines.

Estimated in-country stock duration: Veterinary pharmaceutical stocks are held in smaller quantities relative to annual consumption than human pharmaceuticals, because on-farm use is seasonal and farmers typically purchase as needed. Rough estimates:

Category Estimated NZ stock Approximate duration at normal use
Anthelmintics (drenches, pour-ons) Moderate 6–18 months
Intramammary antibiotics (mastitis) Moderate–high 6–12 months
Injectable antibiotics Moderate 3–12 months
Clostridial vaccines Seasonal stock 6–12 months
Anti-inflammatory drugs Moderate 6–12 months
Mineral supplements (zinc, magnesium, calcium) High (bulky, stockpiled) 12–24 months

These are rough estimates. The national veterinary inventory (Recommended Action 1) would establish actual figures.

1.3 Massey University School of Veterinary Science

Massey University in Palmerston North operates NZ’s only veterinary school and the Veterinary Teaching Hospital — the country’s largest veterinary referral centre.15 This institution is irreplaceable for veterinary training, research, and specialist clinical services. Its continuation under the baseline scenario (grid operational, institutional continuity) is assumed, though its research and teaching priorities must shift dramatically toward production animal medicine, preventive husbandry, and locally producible treatments.

AgResearch (Crown Research Institute) operates laboratories at Wallaceville (Upper Hutt) and several other sites with expertise in animal health, parasitology, and vaccine development.16 These facilities are the foundation for any domestic veterinary pharmaceutical or vaccine production.

2. HOW NUCLEAR WINTER CHANGES THE DISEASE ENVIRONMENT

2.1 The stress-disease interaction

Livestock disease is not random. It follows from the interaction between the animal’s immune status, the pathogen load in the environment, and the stressors the animal faces. Under normal NZ conditions, healthy, well-fed livestock on well-managed pastures have disease incidence that modern veterinary medicine keeps manageable. Nuclear winter disrupts all three elements of this interaction simultaneously:

Reduced nutrition → weakened immunity. Pasture growth declines 25–70% depending on region (Doc #074, Section 2.5). Animals that are chronically underfed have suppressed immune function — reduced antibody production, slower wound healing, increased susceptibility to infection. This is well-established in veterinary immunology and is not specific to nuclear winter; it is the same mechanism that drives disease outbreaks during droughts or severe winters under normal conditions.17

Cold stress → increased energy demand → deeper nutritional deficit. Animals expend more energy maintaining body temperature in colder conditions. A 5 degree C average cooling increases the metabolic energy requirement of cattle by approximately 10–20% (depending on breed, body condition, shelter, and wind exposure).18 This energy comes from feed or body reserves. If feed is already constrained, cold stress drives animals into negative energy balance faster — accelerating the immune suppression described above.

UV increase → pasture quality changes → possible direct effects. Increased UV-B radiation may reduce pasture quality (Doc #19, Section 2.3), affecting the nutritional value of feed. Direct UV effects on livestock health are less certain — most livestock species tolerate moderate UV increases, but skin conditions in light-skinned breeds (Hereford, Charolais, some sheep breeds) could increase, and eye conditions (pink eye, ocular squamous cell carcinoma) may become more prevalent.19

Changed precipitation → altered pathogen survival. If precipitation increases in some regions (nuclear winter models are uncertain on this), wet conditions favour many pathogens — particularly those causing foot rot in sheep, mastitis in cattle, and parasitic larvae survival on pastures.20 If precipitation decreases, different problems emerge (dust, reduced water quality, concentration of animals around remaining water sources).

2.2 Expected disease incidence changes

The following estimates are based on known stress-disease relationships extrapolated to nuclear winter conditions. They are assumptions, not predictions.

Disease Normal incidence/impact Estimated nuclear winter incidence Primary driver
Internal parasites (nematodes) 10–30% growth rate reduction in young stock (managed) 20–50% growth rate reduction (less treatment, more stress) Anthelmintic depletion + immune suppression
Mastitis (dairy cattle) 15–25% of cows per season (clinical) 25–45% of cows per season Cold stress + nutritional stress + reduced dry cow therapy
Facial eczema Regional, seasonal (North Island) Uncertain — may decrease if temperatures drop below fungal optimum, or increase in warm-wet micro-seasons Temperature-dependent spore production
Metabolic disorders (milk fever, ketosis, grass staggers) 5–15% of dairy cows 10–25% of dairy cows Changed feed composition + mineral deficiency
Foot rot (sheep) 5–15% of flock (regional) 10–30% if wet conditions increase Moisture + reduced zinc supplementation
Clostridial diseases (pulpy kidney, tetanus, blackleg) Low (vaccinated) Rising as vaccine stocks deplete Vaccine depletion
Leptospirosis Low (vaccinated dairy herds) Rising as vaccine stocks deplete Vaccine depletion + human health risk
Johne’s disease 5–10% of dairy herds infected Stable or increasing (stress-related expression) Chronic; not pharmaceutical-dependent

3. PRIORITY DISEASES: DETAILED ASSESSMENT

3.1 Internal parasites

What they are: Gastrointestinal nematodes (roundworms) — primarily Ostertagia/Teladorsagia, Cooperia, Haemonchus, Trichostrongylus, and Nematodirus — are the most economically important livestock diseases in NZ pastoral farming. Virtually every grazing animal carries some worm burden. The question is management, not elimination.21

Current management: NZ relies heavily on anthelmintic drenches — chemical treatments administered orally, by injection, or as pour-on formulations. Three main drug families: benzimidazoles (fenbendazole, albendazole), macrocyclic lactones (ivermectin, abamectin, moxidectin), and levamisole. NZ sheep and cattle already have significant anthelmintic resistance — particularly to benzimidazoles and, increasingly, to macrocyclic lactones.22 This pre-existing resistance problem means that even before pharmaceutical depletion, drug efficacy is declining.

Nuclear winter impact: When anthelmintic stocks deplete — likely within 12–24 months — NZ farmers face managing parasites without the drugs that have been the primary tool for 50 years. This is the single largest veterinary challenge.

Non-pharmaceutical management:

  • Pasture rotation. Rotating livestock between paddocks breaks the parasite lifecycle. Larvae deposited in faeces take 2–6 weeks to develop to infective stage on pasture. Moving animals before larvae mature, and not returning them to that pasture for 3–6 months, reduces exposure. NZ’s subdivision and fencing infrastructure supports this, but it requires more paddocks and more labour than set stocking.23
  • Species rotation. Cattle and sheep parasites are largely host-specific. Alternating sheep and cattle on the same pasture reduces each species’ parasite burden. Mixed grazing — running cattle and sheep together or in sequence — is an established NZ practice that should be expanded.24
  • Selective treatment (targeted selective treatment, TST). Rather than drenching all animals, identify and treat only those with high parasite burdens. Faecal egg count (FEC) monitoring identifies heavily parasitised individuals. This conserves drugs, slows resistance development, and maintains a “refugia” population of drug-susceptible parasites on pasture. It requires more monitoring but less drug.25
  • Genetic selection. NZ sheep breeding programmes (particularly through Sheep Improvement Ltd, SIL) already include FEC breeding values — genetic markers for parasite resistance. Rams with low FEC breeding values produce lambs that carry lower worm burdens and require less drenching. Under pharmaceutical scarcity, this breeding criterion should be prioritised heavily.26
  • Biological control. The nematophagous fungus Duddingtonia flagrans traps and kills parasite larvae on pasture. When fed to livestock as spores (in feed or as a bolus), the fungus passes through the gut and germinates in faecal pats, killing larvae before they become infective. This has been commercially developed for horses and is under research for cattle and sheep. NZ has the mycological expertise (Landcare Research, Massey University) to develop local production if a programme is established.27
  • Tannin-rich forages. Chicory, plantain, sainfoin, and some other plants contain condensed tannins that have anthelmintic properties — they reduce parasite burdens when livestock graze them. The effect is moderate (not equivalent to pharmaceutical drenching) but meaningful. These forages can be incorporated into pasture mixes.28

3.2 Mastitis

What it is: Bacterial infection of the udder, the most common and costly disease of dairy cattle worldwide. Causes reduced milk production, contaminated milk, pain, and if untreated can cause quarter loss or death. Primary pathogens: Streptococcus uberis, Staphylococcus aureus, Escherichia coli, and environmental streptococci.29

Current management: Relies heavily on intramammary antibiotic tubes (both for treatment of clinical cases and for “dry cow therapy” — antibiotic infusion at the end of lactation to prevent new infections over the dry period). Milking hygiene, teat spraying with iodine-based teat spray, and culling of chronically infected cows are also standard.

Nuclear winter impact: Mastitis risk increases under cold, wet conditions (more environmental pathogen exposure), nutritional stress (immune suppression), and reduced teat spray availability (iodine is imported). Simultaneously, intramammary antibiotic stocks deplete.

Non-pharmaceutical management:

  • Milking hygiene. Rigorous pre-milking teat cleaning, post-milking teat disinfection, and milking machine maintenance are the foundation of mastitis prevention. Under pharmaceutical scarcity, hygiene becomes more important, not less.
  • Teat spray alternatives. When iodine-based commercial teat sprays deplete, alternatives include: dilute bleach (sodium hypochlorite — producible locally from salt via electrolysis, Doc #63), dilute chlorhexidine (existing stocks), or in extremis, warm soapy water (soap production per Doc #37). These alternatives are measurably inferior to iodine-based sprays: sodium hypochlorite teat dips typically achieve 50–70% of the pathogen kill rate of iodine-based products against environmental streptococci, and soap alone provides mechanical removal but limited antimicrobial action. They are nonetheless substantially better than no post-milking teat disinfection.30
  • Selective dry cow therapy. Rather than treating all cows at dry-off with antibiotics, test each cow (California Mastitis Test, or CMT — a simple on-farm test using a surfactant reagent that can be locally produced) and treat only infected quarters. This can reduce antibiotic consumption for dry cow therapy by 50–70% while maintaining equivalent disease outcomes.31 NZ has been moving toward selective dry cow therapy pre-event; under pharmaceutical scarcity, it becomes mandatory.
  • Culling chronically infected cows. Cows with chronic Staphylococcus aureus mastitis are rarely cured even with antibiotics. Under pharmaceutical scarcity, these cows are a reservoir of infection and a waste of treatment resources. Cull them. The meat is still usable.
  • Once-daily milking. Reduces milking-related udder trauma and new infection risk. Production drops 15–25% (Doc #122), but mastitis incidence typically decreases, and the net food output may be comparable when mastitis treatment costs (antibiotics, discarded milk, labour) are accounted for.32

3.3 Facial eczema

What it is: Facial eczema is caused by sporidesmin, a mycotoxin produced by the saprophytic fungus Pithomyces chartarum that grows on dead pasture litter in warm, humid conditions (typically late summer and autumn in the North Island, increasingly in northern South Island).33 Sporidesmin causes irreversible liver damage. Clinical signs include skin photosensitisation, jaundice, weight loss, and death in severe cases. Sub-clinical liver damage (no visible signs, but reduced production) is far more common than clinical disease.

Current management: Zinc supplementation — oral zinc oxide drenches, zinc boluses, zinc in water — protects the liver against sporidesmin toxicity if given before exposure. Spore counting on pasture allows timing of zinc supplementation. Pasture management (avoiding high-risk paddocks, topping pastures to remove dead litter) and fungicide application reduce spore production. Genetic selection for facial eczema tolerance is well-advanced in some NZ dairy breeds.34

Nuclear winter impact: Uncertain. Facial eczema requires warm, humid conditions (minimum pasture temperature ~12–13 degrees C with adequate moisture). A 5 degree C cooling might reduce spore production in most regions, potentially making facial eczema less of a problem than currently. However, if there are warm-wet periods during the reduced growing season, spore production could still occur, and animals with compromised liver function from nutritional stress would be more vulnerable to any sporidesmin exposure. The critical uncertainty is whether zinc oxide supply is maintained.

Zinc oxide supply: NZ does not mine zinc domestically in large quantities, though zinc-bearing minerals exist (particularly in the West Coast of the South Island).35 Zinc oxide stocks for agricultural use are imported. When stocks deplete, NZ must either develop local zinc extraction or accept increased facial eczema risk. This is a medium-term (Phase 3–4) mineral processing challenge.

Non-pharmaceutical management:

  • Pasture management. Avoid grazing paddocks with high dead-litter content during high-risk periods. Top (mow) pastures to remove dead material. Graze high-risk paddocks with less susceptible species (sheep are less affected than cattle, though not immune).
  • Spore monitoring. Continue pasture spore counts to time risk periods. This requires only a microscope, culture plates, and trained personnel — no imported reagents.
  • Genetic selection. Facial eczema tolerance has moderate heritability. NZ dairy and beef breeding programmes include FE tolerance breeding values. Under pharmaceutical scarcity, selecting bulls with high FE tolerance becomes a priority criterion for North Island herds.36

3.4 Metabolic disorders

What they are: Metabolic disorders result from nutritional imbalances — too much or too little of specific minerals, energy, or protein relative to the animal’s metabolic demands. The most important in NZ:

  • Hypocalcaemia (milk fever): Calcium deficiency around calving. Affects 5–10% of mature dairy cows. Untreated, fatal. Treated with intravenous or subcutaneous calcium borogluconate — an inexpensive, locally producible treatment.37
  • Hypomagnesaemia (grass staggers): Magnesium deficiency, particularly in lactating cows on lush spring pasture low in magnesium. Fatal if untreated. Prevented by magnesium supplementation in water or feed.38
  • Ketosis: Energy deficit in high-producing dairy cows, particularly in early lactation. Less likely to be a major problem under nuclear winter conditions where production is reduced and cows are not being pushed for maximum output.
  • Copper deficiency: Widespread in parts of NZ (particularly Waikato peat soils and pumice soils). Causes poor growth, anaemia, and swayback in lambs. Prevented by copper supplementation.39

Nuclear winter impact: Metabolic disorders will likely increase. Changed pasture composition (less clover, different mineral profiles), reduced feed quality, and inability to import mineral supplements all shift the nutritional balance. Magnesium and calcium disorders are the most acute risks because they kill quickly without treatment.

Local production potential:

  • Calcium borogluconate: The dependency chain: limestone (abundant in NZ — Waikato, Canterbury, Southland) must be calcined to calcium oxide, then reacted with gluconic acid (which requires glucose oxidation, itself requiring a fermentation or chemical oxidation step) and boric acid to produce calcium borogluconate. Boric acid is used in NZ industry and some stock exists; longer-term, NZ has boron-bearing geothermal deposits (Taupo Volcanic Zone). The reaction chemistry is well-understood, but producing a sterile, correctly concentrated injectable solution requires filtered water, calibrated glassware, autoclaving capability, and quality testing — without which IV administration risks fatal air embolism, infection, or calcium toxicity. This is a [B] feasibility target with the sterility requirement as the binding constraint.40
  • Magnesium oxide (causmag): Magnesium-bearing rocks exist in NZ (particularly dolomite in the Nelson region and serpentinite in various locations). Processing to magnesium oxide is achievable with heat treatment (calcination). NZ already has lime kilns (Doc #113) that could be adapted. This is a [B] feasibility production target.41
  • Copper sulfate: More difficult. Copper is not mined in NZ currently, though small deposits exist (e.g., Rahu, West Coast; various Coromandel Peninsula occurrences). The dependency chain is substantial: recycled copper must be sourced (electrical wire, plumbing — Doc #113), cleaned and dissolved in sulfuric acid (which itself requires either imported stocks or local production from pyrite roasting or sulfur, Doc #119), heated and concentrated, then crystallised. Each step requires specific equipment (acid-resistant vessels, temperature control, ventilation for acid fumes) and trained chemical operators. Even at small scale, this is a [C] feasibility production target — achievable only after sulfuric acid production is established. This is a 3–7 year development pathway from standing start.

3.5 Clostridial diseases and vaccine-preventable conditions

What they are: Clostridial bacteria (Clostridium perfringens, C. tetani, C. chauvoei, C. novyi, C. septicum) cause rapidly fatal diseases in livestock — pulpy kidney, tetanus, blackleg, malignant oedema, and black disease. NZ controls these almost entirely through vaccination: the “5-in-1” or “10-in-1” clostridial vaccines given to lambs, calves, and breeding stock are among the most widely used veterinary vaccines in NZ.42

Nuclear winter impact: When vaccine stocks deplete — likely within 12–24 months — clostridial diseases will re-emerge. These diseases killed significant numbers of livestock in NZ before vaccination became standard in the mid-twentieth century. The return to unvaccinated livestock is a return to pre-1950s mortality rates from these causes — historically estimated at 2–5% annual mortality in sheep from pulpy kidney alone in some NZ districts before widespread vaccination.43

Leptospirosis is a particular concern because it is zoonotic — it infects humans as well as animals. NZ has high leptospirosis prevalence in livestock, and dairy farmers are at significant occupational risk. Vaccination of dairy cattle against leptospirosis protects both animals and people. When vaccine supplies deplete, human leptospirosis cases will increase (Doc #75).44

Mitigation without vaccines:

  • Hygiene and management. Some clostridial diseases are associated with specific risk factors: pulpy kidney with sudden feed changes or lush pasture in lambs; blackleg with soil disturbance; tetanus with wounds. Managing these risk factors reduces (but does not eliminate) disease incidence.
  • Local vaccine production. Clostridial vaccines are among the simpler veterinary biologics — they are inactivated toxoid vaccines produced by growing Clostridium species in culture, harvesting the toxin, and inactivating it with formalin. The technology is early-to-mid twentieth century. NZ has the microbiological capability (AgResearch Wallaceville, Massey University) to attempt local production, but quality control — ensuring consistent toxoid potency, sterility, and absence of live organisms — is the real challenge. This is a [B/C] feasibility target requiring 2–5 years of development.45

4. VETERINARY PHARMACEUTICAL TRIAGE

4.1 The allocation dilemma

Veterinary pharmaceuticals serve two purposes: treating animals and (for dual-use drugs) potentially treating humans. When supply is finite, allocation between these uses requires explicit decision-making.

Principle: Animal health serves human food security. The allocation framework should prioritise veterinary drug uses that protect food production. However, when a human life can be saved by a drug that would otherwise treat a non-critical animal condition, human use takes priority. The tension arises in the middle ground — where veterinary use prevents production losses that feed many people, but human use treats a serious (though not immediately fatal) individual illness.

Resolution: The National Pharmaceutical Triage Authority (Doc #116, Section 4.3) must include veterinary representation. Allocation decisions between human and veterinary use should be evidence-based, considering the population-level food security impact of veterinary pharmaceutical depletion against the individual-level health impact of human pharmaceutical shortage.

4.2 Veterinary pharmaceutical priorities

Priority 1 — Protect food production directly:

Drug class Primary veterinary use Annual NZ use (estimate) Human dual-use?
Anthelmintics (ivermectin, fenbendazole, albendazole, levamisole) Parasite control in cattle and sheep High — millions of doses Yes (ivermectin, albendazole for human parasites)
Intramammary antibiotics (cloxacillin, amoxicillin, cephalonium) Mastitis treatment and prevention High — millions of tubes Limited (different formulation)
Zinc oxide (drench formulation) Facial eczema prevention Moderate–high (seasonal) No (different dose form)
Calcium borogluconate Milk fever treatment Moderate No (veterinary-specific use)
Magnesium supplements Grass staggers prevention Moderate Marginal
Clostridial vaccines Prevention of fatal bacterial diseases Very high — millions of doses No

Priority 2 — Important but deferrable:

Drug class Use Notes
Anti-inflammatories (meloxicam, flunixin) Pain relief, fever control Meloxicam is dual-use (human formulation exists)
Anaesthetics (ketamine, lidocaine, xylazine) Surgical procedures Ketamine and lidocaine are high-value dual-use drugs
Injectable antibiotics (penicillin, oxytetracycline) Systemic infection treatment High dual-use potential

Priority 3 — Companion animal medications:

Under pharmaceutical scarcity, companion animal (dog, cat) medications are the lowest veterinary priority. This is a resource allocation decision driven by the food security imperative. Flea treatments, heartworm preventatives, dental anaesthetics, and chronic disease management for pets cannot compete with livestock disease management for scarce pharmaceutical stocks.

This will be socially difficult. NZ has approximately 4.6 million pets (dogs and cats combined).46 Many people regard their companion animals as family members. Public communication must explain the reasoning — food production for NZ’s approximately 5.1–5.2 million people depends on livestock health — without dismissiveness.47

5. LOCALLY PRODUCIBLE VETERINARY TREATMENTS

5.1 What is achievable

Modern veterinary pharmaceuticals cannot be replaced by local production in any timeframe relevant to this document (see Doc #119 for the broader pharmaceutical production assessment). What can be produced locally are treatments that were standard practice before the pharmaceutical era, supplemented by a few modern insights. These are inferior to modern pharmaceuticals — the performance gap is real and should not be minimised — but they extend the treatment toolkit beyond zero.

5.2 Wound care [Feasibility: A/B]

Honey-based wound dressings. Manuka honey (Leptospermum scoparium) has well-documented antibacterial properties due to methylglyoxal (MGO) content and hydrogen peroxide activity.48 NZ produces approximately 15,000–25,000 tonnes of honey annually (pre-event, variable by season), with manuka honey a significant proportion by value though a smaller fraction by volume.49 Under nuclear winter, honey production will decline (reduced flowering, bee stress), but NZ will still produce honey, and its wound care applications in veterinary medicine are well-established. Application: clean wound, apply manuka honey directly, cover with bandage. Effective for superficial wounds, abrasions, and minor infections. Not a replacement for systemic antibiotics for deep or systemic infections.

Tallow-based balms and salves. Animal tallow rendered from destocking operations (Doc #3) can be combined with locally available antiseptic agents — manuka oil (Leptospermum scoparium essential oil — chemically distinct from Australian tea tree oil, Melaleuca alternifolia, but with its own demonstrated antimicrobial properties, particularly against gram-positive bacteria), kawakawa leaf extract (traditional Maori medicine with demonstrated anti-inflammatory properties), or koromiko (Hebe stricta, traditionally used for wound healing) — to produce topical wound care preparations.50 These are folk remedies with varying levels of evidence, but in the absence of commercial wound care products, they provide some antimicrobial and protective function.

Maggot debridement therapy. Controlled application of sterile green bottle fly (Lucilia sericata) larvae to wounds for debridement of necrotic tissue. This is not folk medicine — it is an established medical technique with demonstrated efficacy in both human and veterinary wound care.51 NZ has the relevant fly species. The challenge is producing sterile larvae — this requires a controlled breeding colony with egg sterilisation (typically using dilute sodium hypochlorite), sterile culture medium for larval rearing, and containment to prevent colony contamination. This is achievable with the laboratory facilities available at Massey University or regional hospital laboratories, but not on-farm.

5.3 Mineral supplements [Feasibility: A–C, varies by mineral]

Limestone flour (calcium carbonate). NZ has extensive limestone deposits (Waikato, Canterbury, Otago, Southland). Ground limestone added to drinking water or feed provides calcium supplementation for dairy cattle. This is already standard NZ practice and requires no imported materials — quarrying and grinding infrastructure exists.52

Seaweed supplements. NZ’s extensive coastline provides access to seaweed species high in iodine, selenium, and trace minerals. Dried and ground kelp (bull kelp, Durvillaea, is abundant on NZ’s southern coasts) provides a broad-spectrum mineral supplement. Traditional Maori practice included use of seaweed in animal and human nutrition.53 The mineral content varies by species, season, and location, and should not be relied upon as a sole source of any specific mineral, but as a supplementary source it adds value.

Wood ash. A source of potassium (typically 3–7% K2O), calcium (20–30% CaO), and phosphorus (1–2% P2O5), though mineral content varies significantly by wood species, burn temperature, and soil conditions.54 Can be added to stock feed or water in controlled quantities. Excessive use causes alkalosis — dosing must be managed carefully, with wood ash typically limited to 1–2% of feed dry matter. Compared to commercial mineral supplements with standardised concentrations, wood ash provides unpredictable and lower mineral availability — it is a rough supplementary source, not a substitute for purpose-formulated mineral mixes.

5.4 Herbal anthelmintics [Feasibility: B — plants available, efficacy uncertain]

Honest assessment: No herbal preparation is as effective as modern anthelmintic drugs. Research on plant-based anthelmintics (garlic, wormwood, pumpkin seeds, various tannin-rich plants) shows effects ranging from negligible to moderate, with high variability between studies, plant sources, and target parasite species.55 Under pharmaceutical scarcity, herbal anthelmintics are worth using as part of an integrated parasite management programme (alongside pasture management, genetic selection, and biological control), but they should not be presented as equivalent substitutes.

NZ-available plants with some anthelmintic evidence:

  • Chicory (Cichorium intybus) and plantain (Plantago lanceolata): Condensed tannins and sesquiterpene lactones with demonstrated reduction in FEC in sheep. Already used in NZ pastoral systems as alternative forages.56
  • Karamu (Coprosma robusta) and other native plants: Some NZ native plants have traditional Maori ethnobotanical uses including as anthelmintics. Formal efficacy data is limited. Research by Massey University and Landcare Research on NZ native plant bioactivity is a starting point, but the evidence base is thin.57
  • Garlic and wormwood: Can be grown in NZ. Some evidence for anthelmintic effect in ruminants, but results are inconsistent and doses required are large.58

6. VETERINARY WORKFORCE REDEPLOYMENT

6.1 The rebalancing required

NZ’s veterinary workforce is structured for a peacetime economy where companion animal practice is the largest sector by revenue and employment. Under post-event conditions, the priorities invert: livestock health becomes the overriding concern, and companion animal medicine is a low priority.

Redeployment plan:

  1. All companion animal veterinarians with any large-animal training (most will have received this at veterinary school) are eligible for redeployment to production animal practice. Crash-course retraining (2–4 weeks, delivered by experienced production animal practitioners) covers: common livestock diseases, basic surgical procedures (caesarean section, wound repair), parasite monitoring, calving and lambing assistance, and body condition scoring.
  2. Veterinarians in non-clinical roles (regulatory, academic, corporate) are assessed individually. Those with clinical backgrounds return to practice. Those with research expertise (parasitology, microbiology, pharmacology) are redirected to the local production and vaccine development programmes.
  3. Veterinary nurses and technicians are similarly redeployed. Many have valuable practical skills (anaesthesia monitoring, laboratory testing, surgical assistance) that transfer directly to production animal practice.
  4. Geographic redistribution. Urban veterinary practitioners must relocate to rural areas where livestock are concentrated. This is disruptive to families and communities but necessary. Housing and integration support should be provided.

6.2 Farmer veterinary training

The veterinary workforce cannot attend every sick animal on every farm. Under pharmaceutical scarcity, veterinarians become consultants and trainers rather than front-line treaters. Farmers and farm workers must acquire basic veterinary skills:

Tier 1 skills (all farmers, within 6 months): - Body condition scoring (cattle and sheep) - Recognising common diseases (mastitis detection, parasite signs, metabolic disorder signs, lameness scoring) - Basic wound cleaning and dressing - Calving and lambing assistance (normal and simple dystocia) - Administering oral drenches and injections - Faecal egg count sample collection

Tier 2 skills (selected farmers, within 12 months): - Faecal egg count analysis (microscope use — basic optical microscopes will be available) - California Mastitis Test interpretation - Simple surgical procedures (castration, tail docking, abscess drainage) - Hoof trimming and foot rot treatment - Emergency treatment of metabolic disorders (calcium, magnesium administration)

Tier 3 skills (farm veterinary technicians, within 2 years): - Pregnancy diagnosis - Assisted caesarean section (under veterinary supervision initially) - Basic post-mortem examination for disease diagnosis - Regional disease surveillance reporting

CRITICAL UNCERTAINTIES

Uncertainty Range Impact
Actual veterinary pharmaceutical stock levels Unknown until inventory completed Determines timeline for transition to non-pharmaceutical management
Anthelmintic resistance prevalence at time of event Already significant; exact levels unknown across all regions Drugs may be less effective than assumed even before depletion
Nuclear winter effect on facial eczema risk May decrease (cooler) or persist in warm micro-seasons Determines zinc supplementation urgency
Feasibility of local clostridial vaccine production [B/C] — capability exists at AgResearch but not at production scale Determines whether vaccine-preventable diseases become permanently uncontrolled
Effectiveness of non-pharmaceutical parasite management Moderate under research conditions; unknown at national scale If ineffective, parasite-related growth rate losses in young stock could reach 40–60%, significantly reducing meat and wool output
Cold stress severity on livestock Depends on actual temperature reduction and shelter availability Determines metabolic disorder incidence and feed deficit
Veterinary workforce retention Some overseas-trained vets may attempt to leave NZ Determines actual available workforce
Honey production under nuclear winter Likely reduced significantly (cold, UV, reduced flowering) Determines availability of manuka honey for wound care

Cross-References

  • Doc #020 — Pharmaceutical Reference — Baseline reference for drug classes, dosing ranges, and storage requirements applicable to the dual-use veterinary pharmaceuticals identified in Section 4.2; essential background for the joint veterinary-medical triage board.
  • Doc #074 — Pastoral Farming Under Nuclear Winter — Primary companion document; this document addresses the animal health dimension of the pastoral system described there. Livestock disease losses feed directly into the production estimates in Doc #074.
  • Doc #075 — Cropping and Dairy Adaptation Under Nuclear Winter — Alternative and supplementary feed crops (fodder beet, turnips, kale, chicory, plantain) interact with parasite management and metabolic disorder risk; tannin-rich forage species discussed here are grown under the cropping regimes described there.
  • Doc #083 — Beekeeping Adaptation — Manuka honey production (Section 5.2) depends on hive survival and forage availability under nuclear winter; beekeeping continuation directly affects wound care capacity for both human and veterinary medicine.
  • Doc #085 — Animal Breeding and Genetic Diversity — Genetic selection for disease resistance (facial eczema tolerance, FEC breeding values, parasite resistance) is a primary non-pharmaceutical management strategy throughout this document; breeding decisions made under Doc #085 have direct consequences for veterinary disease burden.
  • Doc #116 — Pharmaceutical Rationing and Shelf-Life Extension — Critical dependency and competition point: veterinary pharmaceuticals draw from the same finite national stock as human medicines. The allocation framework in Doc #116 must explicitly govern dual-use drug decisions (ivermectin, ketamine, lidocaine, penicillin, meloxicam) between veterinary and human use. Animal health and human health compete for the same scarce supply.
  • Doc #119 — Local Pharmaceutical Production: Honest Assessment — Veterinary pharmaceutical production (Section 5.1) is a subset of the broader local production programme assessed there; feasibility ratings for local clostridial vaccine production and mineral supplement synthesis depend on the industrial chemistry capability assessed in Doc #119.

Additional related documents:

  • Doc #001 — Stockpile Strategy — Veterinary pharmaceutical stocks are requisition-eligible assets under the national inventory; on-farm veterinary stocks held by farmers must be included in the national stockpile assessment.
  • Doc #003 — Food Rationing — Animal health losses translate directly into food supply shortfalls; disease-related production reductions must be factored into rationing calculations.
  • Doc #077 — Seed Preservation — Seed stocks for tannin-rich forages (chicory, plantain, sainfoin) required for the parasite management programme in Section 3.1.
  • Doc #080 — Soil Fertility — Mineral deficiencies in NZ soils (copper, selenium, magnesium) drive livestock metabolic disorders; soil management decisions affect the incidence of conditions described in Section 3.4.
  • Doc #125 — Public Health Surveillance — Zoonotic disease monitoring (leptospirosis, campylobacter, Q fever) links animal health directly to human health; leptospirosis vaccine depletion is a shared concern for both this document and Doc #125.
  • Doc #160 — Heritage Skills Preservation — Pre-pharmaceutical veterinary knowledge held by retiring practitioners must be captured under the heritage skills programme; this document identifies the specific veterinary knowledge domains to prioritise.

FOOTNOTES

  1. NZ livestock numbers from Stats NZ Agricultural Production Statistics. https://www.stats.govt.nz/topics/agriculture — Figures are approximate and fluctuate annually. The relationship between livestock health and food security is developed throughout this document and in Doc #074.↩︎

  2. Veterinary Council of New Zealand (VCNZ) workforce data. https://www.vetcouncil.org.nz/ — The VCNZ maintains the register of practising veterinarians in NZ. The total registered number is approximately 3,000–3,200, though not all are actively practising in clinical roles. The proportion in production animal practice (approximately 40–50%) is an estimate based on VCNZ workforce surveys and NZ Veterinary Association (NZVA) membership data. The figure has been declining over recent decades as companion animal practice has grown.↩︎

  3. Duddingtonia flagrans biological control of nematode parasites: Larsen, M. (1999), “Biological control of helminths,” International Journal for Parasitology 29(1):139–146. NZ-specific research: Waghorn, T.S. et al. (2003), “Effect of the fungus Duddingtonia flagrans on the development of free-living stages of sheep intestinal nematodes,” NZ Veterinary Journal 51(3):111–120.↩︎

  4. Food production estimates from Doc #074 (Pastoral Farming Under Nuclear Winter). The conversion from gross pasture energy to human-available food energy accounts for the approximately 5–15% caloric efficiency of ruminant livestock. See also: Smil, V. (2000), “Feeding the World,” MIT Press.↩︎

  5. NZ population: Stats NZ estimated resident population. https://www.stats.govt.nz/topics/population — NZ’s estimated resident population is approximately 5.1–5.2 million as of mid-2020s data. Caloric requirement estimate assumes reduced physical activity rationing levels of 1,900–2,100 kcal/person/day (see Doc #003, Food Rationing).↩︎

  6. Mastitis costs and incidence in NZ: Dairy NZ Mastitis Focus programme data. https://www.dairynz.co.nz/animal/cow-health/mastitis/ — NZ dairy industry estimates of mastitis costs vary by year and methodology. The NZ$180–280 million figure is based on DairyNZ and industry analyses. Clinical mastitis incidence of 15–25% of cows per season is consistent with NZ dairy industry monitoring data.↩︎

  7. Internal parasite impact on livestock production: Vlassoff, A. and McKenna, P.B. (1994), “Nematode parasites of economic importance in sheep in New Zealand,” NZ Journal of Zoology 21(1):1–8. Also: Leathwick, D.M. et al. (2015), “Managing anthelmintic resistance in New Zealand,” NZ Veterinary Journal 63(5):262–267. Growth rate reduction estimates of 10–30% in untreated young stock are based on multiple NZ grazing trials.↩︎

  8. Facial eczema in NZ: Di Menna, M.E. et al. (2009), “Pithomyces chartarum spore counts, facial eczema and liver enzymes,” NZ Veterinary Journal 57(3):138–145. Also: Morris, C.A. et al. (2013), “Genetic parameters for resistance to facial eczema in dairy cattle,” NZ Journal of Agricultural Research 56(4):317–326. The zinc oxide prevention protocol and sporidesmin toxicology are well-established in NZ veterinary science.↩︎

  9. Metabolic disorder incidence in NZ dairy cattle: Lean, I.J. et al. (2006), “Hypocalcaemia in dairy cows: meta-analysis and dietary cation anion difference theory revisited,” Journal of Dairy Science 89(2):669–684. NZ-specific data from DairyNZ health monitoring: https://www.dairynz.co.nz/animal/cow-health/ — Incidence estimates vary by region, breed, and management system.↩︎

  10. NZ farm numbers: Stats NZ Agricultural Production Statistics. The number of farms in NZ depends on definition — Stats NZ reports approximately 50,000–55,000 agricultural holdings, but many are small lifestyle blocks. The number of commercially significant livestock farms is lower, perhaps 35,000–40,000. The training programme should target all holdings with meaningful livestock numbers.↩︎

  11. Veterinary Council of New Zealand (VCNZ) workforce data. https://www.vetcouncil.org.nz/ — The VCNZ maintains the register of practising veterinarians in NZ. The total registered number is approximately 3,000–3,200, though not all are actively practising in clinical roles. The proportion in production animal practice (approximately 40–50%) is an estimate based on VCNZ workforce surveys and NZ Veterinary Association (NZVA) membership data. The figure has been declining over recent decades as companion animal practice has grown.↩︎

  12. Veterinary nursing workforce estimates based on NZ Veterinary Nursing Association data and VCNZ-registered veterinary nurse numbers. Exact figures are approximate as registration requirements have changed.↩︎

  13. Provet NZ (EBOS Group subsidiary). https://www.provet.co.nz/ — NZ’s primary veterinary pharmaceutical and supplies distributor. See also Doc #116, footnote 35.↩︎

  14. PGG Wrightson and Farmlands store counts: PGG Wrightson Limited Annual Report and Farmlands Co-operative Society Annual Report. Store counts are approximate and subject to periodic closures and openings. These figures require verification from current company data.↩︎

  15. Massey University School of Veterinary Science. https://www.massey.ac.nz/about/colleges-schools-and-insti... — NZ’s sole veterinary school, established 1963. Produces approximately 90–100 veterinary graduates per year. Operates the Veterinary Teaching Hospital in Palmerston North.↩︎

  16. AgResearch. https://www.agresearch.co.nz/ — Crown Research Institute with extensive animal health research capability. The Wallaceville campus (Upper Hutt) has historically been NZ’s primary animal health laboratory, with expertise in parasitology, vaccinology, and diagnostic pathology.↩︎

  17. Nutritional immunology in ruminants: Colditz, I.G. (2002), “Effects of the immune system on metabolism: implications for production and disease resistance in livestock,” Livestock Production Science 75(3):257–268. The relationship between nutritional stress and immune suppression is well-established across all livestock species.↩︎

  18. Cold stress and energy requirements in cattle: Young, B.A. (1981), “Cold stress as it affects animal production,” Journal of Animal Science 52(1):154–163. The 10–20% increase in metabolic energy requirement for a 5 degree C temperature decrease is an approximation depending on breed, insulation (body condition, hair coat), wind exposure, and precipitation. Beef breeds with thick coats are less affected than dairy breeds.↩︎

  19. UV effects on livestock: Gargano, R.G. et al. (2023), “Ultraviolet radiation and its impact on livestock production,” in Environmental Stressors in Animal Production. Ocular and skin effects of increased UV-B are documented in light-skinned cattle breeds. NZ already has relatively high ambient UV due to ozone thinning over the Southern Hemisphere; further increases compound this existing exposure.↩︎

  20. Moisture and livestock disease: West, D.M. et al. (2009), “Diseases of Sheep,” NZ Veterinary Association. Wet conditions favour survival of gastrointestinal parasite larvae, environmental mastitis pathogens, and footrot-causing bacteria (Dichelobacter nodosus).↩︎

  21. Internal parasite impact on livestock production: Vlassoff, A. and McKenna, P.B. (1994), “Nematode parasites of economic importance in sheep in New Zealand,” NZ Journal of Zoology 21(1):1–8. Also: Leathwick, D.M. et al. (2015), “Managing anthelmintic resistance in New Zealand,” NZ Veterinary Journal 63(5):262–267. Growth rate reduction estimates of 10–30% in untreated young stock are based on multiple NZ grazing trials.↩︎

  22. Anthelmintic resistance in NZ: Waghorn, T.S. et al. (2006), “Prevalence of anthelmintic resistance on sheep farms in New Zealand,” NZ Veterinary Journal 54(6):271–277. Also: Leathwick, D.M. et al. (2015), as cited above. NZ has documented resistance to all three major anthelmintic drug families, with benzimidazole resistance particularly widespread.↩︎

  23. Pasture management for parasite control: Barger, I.A. (1999), “The role of epidemiological knowledge and grazing management for helminth control in small ruminants,” International Journal for Parasitology 29(1):41–47. NZ-specific: Vlassoff, A. et al. (2001), “Sustainable control of gastrointestinal nematodes in small ruminants,” NZ Veterinary Journal 49(5):181–188.↩︎

  24. Pasture management for parasite control: Barger, I.A. (1999), “The role of epidemiological knowledge and grazing management for helminth control in small ruminants,” International Journal for Parasitology 29(1):41–47. NZ-specific: Vlassoff, A. et al. (2001), “Sustainable control of gastrointestinal nematodes in small ruminants,” NZ Veterinary Journal 49(5):181–188.↩︎

  25. Targeted selective treatment: Kenyon, F. et al. (2009), “The role of targeted selective treatments in the development of refugia-based approaches to the control of gastrointestinal nematodes of small ruminants,” Veterinary Parasitology 164(1):3–11. Also: Leathwick, D.M. (2013), “The influence of temperature on the development and survival of the free-living stages of nematode parasites of sheep,” NZ Veterinary Journal 61(1):32–40.↩︎

  26. Genetic selection for parasite resistance in NZ sheep: Morris, C.A. et al. (2000), “Responses of Romney sheep to selection for resistance or susceptibility to nematode infection,” Animal Science 70(3):353–361. SIL (Sheep Improvement Limited) breeding value data: https://www.sil.co.nz/ — FEC breeding values are routinely available for NZ sheep sires.↩︎

  27. Duddingtonia flagrans biological control of nematode parasites: Larsen, M. (1999), “Biological control of helminths,” International Journal for Parasitology 29(1):139–146. NZ-specific research: Waghorn, T.S. et al. (2003), “Effect of the fungus Duddingtonia flagrans on the development of free-living stages of sheep intestinal nematodes,” NZ Veterinary Journal 51(3):111–120.↩︎

  28. Bioactive forages and parasite control: Tzamaloukas, O. et al. (2006), “Chicory and parasites,” NZ Journal of Agricultural Research 49(2):179–186. Also: Marley, C.L. et al. (2003), “The effect of birdsfoot trefoil (Lotus corniculatus) and chicory (Cichorium intybus) on parasite intensities and performance of lambs,” Veterinary Parasitology 112(1–2):147–155.↩︎

  29. Mastitis costs and incidence in NZ: Dairy NZ Mastitis Focus programme data. https://www.dairynz.co.nz/animal/cow-health/mastitis/ — NZ dairy industry estimates of mastitis costs vary by year and methodology. The NZ$180–280 million figure is based on DairyNZ and industry analyses. Clinical mastitis incidence of 15–25% of cows per season is consistent with NZ dairy industry monitoring data.↩︎

  30. Teat disinfection alternatives: Gleeson, D.E. et al. (2009), “Effect of teat disinfection on mastitis,” Irish Veterinary Journal 62(9):1–5. Sodium hypochlorite as teat disinfectant has demonstrated efficacy though typically inferior to iodine-based products. Any teat disinfection is substantially better than none.↩︎

  31. Selective dry cow therapy: Cameron, M. et al. (2014), “Evaluation of selective dry cow treatment following on-farm culture,” Journal of Dairy Science 97(11):6730–6744. NZ studies: McDougall, S. et al. (2019), “Randomized clinical trial of selective dry cow therapy in New Zealand dairy herds,” Journal of Dairy Science 102(8):7276–7286. Demonstrated comparable outcomes to blanket dry cow therapy with 50–70% reduction in antibiotic use.↩︎

  32. Once-daily milking and mastitis: Clark, D.A. et al. (2006), “A systems comparison of once- versus twice-daily milking of pastured dairy cows,” Journal of Dairy Science 89(5):1854–1862. Mastitis incidence is generally lower under once-daily milking, likely due to reduced mechanical trauma and reduced teat canal opening time.↩︎

  33. Facial eczema in NZ: Di Menna, M.E. et al. (2009), “Pithomyces chartarum spore counts, facial eczema and liver enzymes,” NZ Veterinary Journal 57(3):138–145. Also: Morris, C.A. et al. (2013), “Genetic parameters for resistance to facial eczema in dairy cattle,” NZ Journal of Agricultural Research 56(4):317–326. The zinc oxide prevention protocol and sporidesmin toxicology are well-established in NZ veterinary science.↩︎

  34. Facial eczema in NZ: Di Menna, M.E. et al. (2009), “Pithomyces chartarum spore counts, facial eczema and liver enzymes,” NZ Veterinary Journal 57(3):138–145. Also: Morris, C.A. et al. (2013), “Genetic parameters for resistance to facial eczema in dairy cattle,” NZ Journal of Agricultural Research 56(4):317–326. The zinc oxide prevention protocol and sporidesmin toxicology are well-established in NZ veterinary science.↩︎

  35. NZ zinc resources: NZ Petroleum and Minerals, Ministry of Business, Innovation and Employment. Some zinc-bearing mineralization exists in the West Coast and Otago regions but NZ has no operational zinc mines. NZ imports zinc for agricultural and industrial use.↩︎

  36. Facial eczema in NZ: Di Menna, M.E. et al. (2009), “Pithomyces chartarum spore counts, facial eczema and liver enzymes,” NZ Veterinary Journal 57(3):138–145. Also: Morris, C.A. et al. (2013), “Genetic parameters for resistance to facial eczema in dairy cattle,” NZ Journal of Agricultural Research 56(4):317–326. The zinc oxide prevention protocol and sporidesmin toxicology are well-established in NZ veterinary science.↩︎

  37. Metabolic disorder incidence in NZ dairy cattle: Lean, I.J. et al. (2006), “Hypocalcaemia in dairy cows: meta-analysis and dietary cation anion difference theory revisited,” Journal of Dairy Science 89(2):669–684. NZ-specific data from DairyNZ health monitoring: https://www.dairynz.co.nz/animal/cow-health/ — Incidence estimates vary by region, breed, and management system.↩︎

  38. Metabolic disorder incidence in NZ dairy cattle: Lean, I.J. et al. (2006), “Hypocalcaemia in dairy cows: meta-analysis and dietary cation anion difference theory revisited,” Journal of Dairy Science 89(2):669–684. NZ-specific data from DairyNZ health monitoring: https://www.dairynz.co.nz/animal/cow-health/ — Incidence estimates vary by region, breed, and management system.↩︎

  39. Copper deficiency in NZ livestock: Grace, N.D. (1994), “Managing Trace Element Deficiencies,” NZ Pastoral Agriculture Research Institute. Copper deficiency is widespread in parts of NZ due to naturally low soil copper or high molybdenum/sulfur levels that antagonise copper absorption.↩︎

  40. Limestone resources in NZ are extensive. Christie, A.B. and Barker, R.G. (2007), “Mineral Wealth of New Zealand,” GNS Science Monograph 33. Calcium carbonate processing to calcium borogluconate for veterinary injection is standard chemistry but requires sterility controls for parenteral formulations.↩︎

  41. Magnesium oxide production from dolomite: dolomite deposits exist in the Nelson/Marlborough region and other locations. Calcination of dolomite (heating to approximately 700–900 degrees C) produces magnesium oxide. This is achievable with existing lime kiln technology. See Doc #112 for cement/lime production infrastructure.↩︎

  42. Clostridial vaccination in NZ: West, D.M. et al. (2009), “Diseases of Sheep,” NZ Veterinary Association. Clostridial vaccines are the most widely used veterinary vaccines in NZ, with annual doses numbering in the tens of millions across sheep, cattle, and deer.↩︎

  43. Pre-vaccination clostridial disease mortality in NZ sheep: West, D.M. et al. (2009), “Diseases of Sheep,” NZ Veterinary Association. Also: historical NZ Department of Agriculture annual reports from the 1930s–1950s document pulpy kidney as a leading cause of lamb mortality prior to the introduction of clostridial vaccines in the mid-twentieth century.↩︎

  44. Leptospirosis in NZ: Dreyfus, A. et al. (2014), “Leptospirosis seroprevalence and risk factors in health care workers in New Zealand,” International Journal of Environmental Research and Public Health 11(2):1756–1775. Also: Thornley, C.N. et al. (2002), “Surveillance report: notifiable and other diseases in New Zealand,” NZ Public Health Report 9(8):57–64. NZ has among the highest notified leptospirosis rates in the developed world, with dairy farmers at particular occupational risk.↩︎

  45. Clostridial vaccine production technology: vaccines based on formalin-inactivated toxoids have been produced since the early twentieth century. The basic production method (anaerobic culture of Clostridium spp., toxin harvest, formalin inactivation, adjuvanting with aluminium salts) is well-described in veterinary vaccine manufacturing literature. Quality control — particularly potency testing (mouse or guinea pig challenge tests or in vitro alternatives) and sterility assurance — is the primary barrier to local production.↩︎

  46. NZ companion animal population: Companion Animals in New Zealand, NZ Companion Animal Council. Approximately 4.6 million companion animals (dogs and cats combined), with approximately 64% of NZ households owning at least one pet.↩︎

  47. NZ population: Stats NZ estimated resident population. https://www.stats.govt.nz/topics/population — NZ’s estimated resident population is approximately 5.1–5.2 million as of mid-2020s data. Caloric requirement estimate assumes reduced physical activity rationing levels of 1,900–2,100 kcal/person/day (see Doc #003, Food Rationing).↩︎

  48. Manuka honey antimicrobial properties: Molan, P.C. (2006), “The evidence and the rationale for the use of honey as a wound dressing,” Wound Practice and Research 14(3):148–158. Also: Carter, D.A. et al. (2016), “Therapeutic Manuka Honey: No Longer So Alternative,” Frontiers in Microbiology 7:569. Methylglyoxal (MGO) content is the primary non-peroxide antibacterial component specific to manuka honey.↩︎

  49. NZ honey production: Ministry for Primary Industries, Apiculture Monitoring Reports. https://www.mpi.govt.nz/ — NZ produces approximately 15,000–25,000 tonnes of honey annually (variable by year and season). Manuka honey represents a significant portion of production value though a smaller proportion by volume.↩︎

  50. Rongoa Maori (traditional Maori medicine): Brooker, S.G., Cambie, R.C., and Cooper, R.C. (1987), “New Zealand Medicinal Plants,” Heinemann. Also: Riley, M. (1994), “Maori Healing and Herbal,” Viking Sevenseas. Kawakawa (Piper excelsum) has demonstrated anti-inflammatory activity; koromiko (Hebe stricta) has traditional wound-healing applications. Scientific validation of efficacy for these and other rongoa is limited but growing.↩︎

  51. Maggot debridement therapy: Sherman, R.A. (2009), “Maggot Therapy Takes Us Back to the Future of Wound Care,” Journal of Diabetes Science and Technology 3(2):336–344. The technique uses sterile Lucilia sericata larvae. It is an accepted medical therapy (FDA-cleared in the US) and has been used in both human and veterinary medicine.↩︎

  52. Limestone resources in NZ are extensive. Christie, A.B. and Barker, R.G. (2007), “Mineral Wealth of New Zealand,” GNS Science Monograph 33. Calcium carbonate processing to calcium borogluconate for veterinary injection is standard chemistry but requires sterility controls for parenteral formulations.↩︎

  53. Seaweed as livestock mineral supplement: Makkar, H.P.S. et al. (2016), “Seaweeds for livestock diets: A review,” Animal Feed Science and Technology 212:1–17. NZ kelp species (Durvillaea, Macrocystis) are rich in iodine and contain variable levels of other trace minerals. Traditional Maori use of seaweed in agriculture and nutrition is documented in ethnobotanical literature.↩︎

  54. Wood ash mineral content: Etiegni, L. and Campbell, A.G. (1991), “Physical and chemical characteristics of wood ash,” Bioresource Technology 37(2):173–178. Mineral content varies substantially with wood species, combustion temperature, and degree of charring. The ranges given are indicative of hardwood ash under controlled combustion.↩︎

  55. Herbal anthelmintics: Githiori, J.B., Athanasiadou, S., and Thamsborg, S.M. (2006), “Use of plants in novel approaches for control of gastrointestinal helminths in livestock with emphasis on small ruminants,” Veterinary Parasitology 139(4):308–320. The evidence for herbal anthelmintic efficacy is mixed: some plant preparations show moderate effect in controlled trials, while others show no significant effect. Consistency of preparation and dosing is a major challenge.↩︎

  56. Bioactive forages and parasite control: Tzamaloukas, O. et al. (2006), “Chicory and parasites,” NZ Journal of Agricultural Research 49(2):179–186. Also: Marley, C.L. et al. (2003), “The effect of birdsfoot trefoil (Lotus corniculatus) and chicory (Cichorium intybus) on parasite intensities and performance of lambs,” Veterinary Parasitology 112(1–2):147–155.↩︎

  57. NZ native plant bioactivity: Cambie, R.C. and Ferguson, L.R. (2003), “Potential functional foods in the traditional Maori diet,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 523:109–117. Also: various Landcare Research and Massey University studies on NZ native plant phytochemistry. The database of NZ native plant bioactivity is growing but remains limited relative to Northern Hemisphere pharmacopoeia.↩︎

  58. Herbal anthelmintics: Githiori, J.B., Athanasiadou, S., and Thamsborg, S.M. (2006), “Use of plants in novel approaches for control of gastrointestinal helminths in livestock with emphasis on small ruminants,” Veterinary Parasitology 139(4):308–320. The evidence for herbal anthelmintic efficacy is mixed: some plant preparations show moderate effect in controlled trials, while others show no significant effect. Consistency of preparation and dosing is a major challenge.↩︎

← Back to Library Index